The FDA approval of Oveporexton (Orzeyful) marks more than…

The FDA approval of Oveporexton (Orzeyful) marks more than the launch of a new therapy—it represents a shift in how we think about treating rare neurological disorders.

For years, narcolepsy type 1 has been managed by addressing individual symptoms. This approval introduces a therapy designed to restore orexin signaling, targeting the biological mechanism behind the disease.

It's an exciting example of how advances in neuroscience are translating into therapies that have the potential to redefine patient care and improve everyday quality of life.

The infographic highlights why this approval is being considered a significant milestone in sleep medicine.

What other disease areas do you think are on the verge of similar mechanism-based breakthroughs?

#SleepMedicine #Neuroscience #FDAApproval #Innovation #RareDisease #ClinicalResearch #Healthcare #Pharma